Integrating Systemic Therapy Into cSCC Management

Panelists highlight that immune checkpoint inhibition has transformed the management of advanced cutaneous squamous cell carcinoma (cSCC), providing durable responses and improved survival. Candidates include patients with locally advanced or metastatic disease not amenable to surgery or radiation.

Integration requires coordination between dermatology, oncology, and surgical teams to determine sequencing and manage immune-related adverse events. Multidisciplinary tumor boards ensure alignment between systemic and local therapy.

They conclude that systemic therapy now represents a pivotal component of comprehensive cSCC management, bridging curative and palliative intent with meaningful clinical benefit.